about
Clinical Pharmacokinetics of MetforminSafe disposal of prescribed medicinesDiagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysisInterdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.Analysis of population pharmacokinetic data using NONMEM and WinBUGS.Patterns of use and appropriateness of antibiotics prescribed to patients receiving haemodialysis: an observational studyMonte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesResveratrol--pills to replace a healthy diet?The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitusPharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisA systematic review of medication exposure assessment in prospective cohort studies of community dwelling older australians.The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity.Principles and clinical application of assessing alterations in renal elimination pathways.Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review.Characterising the Transmission Dynamics of Acinetobacter baumannii in Intensive Care Units Using Hidden Markov ModelsClinical medication review in Australia: A systematic review.Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.The pharmacokinetics of oxypurinol in people with gout.Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia.Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial cultureBeta-lactam allergy in adults with cystic fibrosis.Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.Inhibition of flucloxacillin tubular renal secretion by piperacillinModeling the impact of interventions against Acinetobacter baumannii transmission in intensive care units.Target concentration intervention in oncology: where are we at?Quality Use of Medicines--medication safety issues in naming; look-alike, sound-alike medicine names.Comparison of 2 weight-based heparin dosing nomograms in neurology and vascular surgical patients.Optimizing hospital infection control: the role of mathematical modeling.Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.Pharmacist-led medication review in community settings: An overview of systematic reviews.Identification of major factors in Australian primary care pharmacists.Why is polypharmacy increasing in aged care facilities? The views of Australian health care professionals.Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.Reducing Medical Admissions into Hospital through Optimising Medicines (REMAIN HOME) Study: protocol for a stepped-wedge, cluster-randomised trial.
P50
Q22241422-B4D2DFD6-9B0E-4C42-BE7F-505AA7B8EE38Q26773292-C80AAEBE-1E32-4149-8646-A903D93F2AFAQ28289614-DD9FF494-B704-48BB-8728-E4B68305A507Q30398368-6E839E01-9450-4C1F-98E6-93DA0E05355FQ30982415-47A19B78-80CA-4293-8BB4-08E07631A228Q33667585-A63BA356-E1A8-461D-BC20-5CC2571849D4Q33759273-D6C47159-737D-4BAD-8B33-23CAE6EEF7E9Q34953705-EC080BED-AF24-486D-8F27-7E67BE4BC155Q35120581-0AC87CBF-26DC-492A-A21B-4D7C9C96711CQ35286089-65351BCE-9B59-4C29-8D9F-1C4FC1E952EFQ35286102-E944145B-D226-4E2C-91E0-C6A58C7E7083Q35535726-B34F7CC4-64DA-4833-A6BE-512A71E39EAEQ35543018-2AFECD58-7EB9-4123-B02D-8A2BEFF9638EQ35579407-34EAD9E8-39A3-424B-BEFD-BB312764D866Q35598414-48A7131C-C371-40D4-A9AF-2B5DD5079FCBQ35600585-46683621-DA70-47A5-93FF-CD50B8C1D004Q35679653-C24DDB95-0874-4A81-8084-6D3045AB962AQ35739325-0DA17AE9-E8A2-40F4-BA83-0B8847743413Q35826231-1092CFCB-F1B6-4A06-8BDE-C243E02C91DCQ36053463-BFCE99CC-FF1D-41AF-A753-4501D59C823BQ36336035-6E220418-22BC-43A3-A41B-9B8096A3F8D4Q36472544-2857E151-7DB8-4D7E-9C0D-6104A6D6DEC8Q36505504-AB3C8452-91A3-45E5-AAA1-B4C5933606BFQ36558478-09057929-4586-4648-B7A4-08C2D9C8E8BDQ36689470-4B95922E-209A-40CF-9BDE-8AE1BBA93B8EQ36946346-C77E3B77-5E7B-4A1A-80B7-CBD49E9E91EEQ37142437-80903B43-928A-467F-BB68-B248126F6E18Q37197347-A7BB3A73-E2CD-4E8B-A87B-5EF11C80A399Q38010071-93A87AAE-4659-4CC6-94A7-D9B06BBFA57DQ38058343-7A9BE57E-6E4D-45E7-9351-101D50AA46ACQ38211998-8D2A5F1A-8399-4F50-B9FE-E2CFDDD81293Q38270848-03940F3B-5466-446A-9AEC-9C15A35511C4Q38620631-E0D8F5F8-72AB-4E37-976E-5D807575A424Q38815563-6654E864-F572-4072-BBEA-E5BE17A012F0Q38818004-FAE7A0A6-E9D1-40ED-9FDF-6A6F127EB39CQ38820885-C42806B2-F73A-468A-8964-5D5AF023E856Q38916828-E2F3316E-633C-44CB-9607-937D4E4EFA20Q38976642-4F58659B-1F65-4D74-AA04-EB8F07A1771FQ39122391-C743075B-2237-4838-9F6A-27C75A6D0D84Q39241602-F71E05E2-D8E9-4835-8D16-244E36EE3EA1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carl M Kirkpatrick
@nl
Carl M Kirkpatrick
@sl
Carl M. Kirkpatrick
@en
Carl M. Kirkpatrick
@es
type
label
Carl M Kirkpatrick
@nl
Carl M Kirkpatrick
@sl
Carl M. Kirkpatrick
@en
Carl M. Kirkpatrick
@es
prefLabel
Carl M Kirkpatrick
@nl
Carl M Kirkpatrick
@sl
Carl M. Kirkpatrick
@en
Carl M. Kirkpatrick
@es
P106
P1153
15925293100
P21
P31
P496
0000-0002-5715-1534